Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 48.1 kDa. The protein migrates as 60-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human CD40 Protein, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Biotinylated Human CD40 Protein, Fc,Avitag (Cat. No. TN5-H82F9) is more than 90% and the molecular weight of this protein is around 105-120 kDa verified by SEC-MALS.
Immobilized Human CD40 Ligand, His,Flag Tag, premium grade (Cat. No. CDL-H52Db) at 5 μg/mL (100 μL/well) can bind Biotinylated Human CD40, Fc,Avitag (Cat. No. TN5-H82F9) with a linear range of 0.01-0.625 μg/mL (QC tested).
Immobilized Biotinylated Human CD40, Fc,Avitag (Cat. No. TN5-H82F9) at 5 μg/mL (100 μL/well) on streptavidin precoated (0.5 μg/well) plate, can bind Human CD40 Ligand, His,Flag Tag, premium grade (Cat. No. CDL-H52Db) with a linear range of 0.039-1.25 μg/mL (Routinely tested).
FACS analysis shows that Biotinylated Human CD40, Fc,Avitag (Cat. No. TN5-H82F9) can bind to 293T cells overexpressing human CD40L. The concentration of Biotinylated Human CD40 is 0.1 μg/mL (Routinely tested).
Price(EUR) : €350.00
Price(EUR) : €1540.00
Price(EUR) : €30.00
Price(EUR) : €140.00
Price(EUR) : €50.00
Price(EUR) : €120.00
Price(EUR) : €140.00
Price(EUR) : €230.00
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CD40L-GVAX | GM.CD40L; CD40L-GVAX; GM-CSF/CD40L; hCD40L/hGM-CSF | Phase 2 Clinical | University Of South Florida | Leukemia; Small Cell Lung Carcinoma; Myelodysplastic Syndromes; Adenocarcinoma of Lung; Lung Neoplasms; Adenocarcinoma; Melanoma | Details |
Giloralimab | ABBV-927 | Phase 2 Clinical | Abbvie Inc | Solid tumours; Head and Neck Neoplasms; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
BI-655064 | BI-655064 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Purpura, Thrombocytopenic, Idiopathic; Arthritis, Rheumatoid; Lupus Nephritis | Details |
Mitazalimab | ADC-1013; JNJ-7107; JNJ-64457107 | Phase 2 Clinical | Alligator Bioscience Ab | Solid tumours; Pancreatic Neoplasms; Neoplasms; Carcinoma, Pancreatic Ductal | Details |
Sotigalimab | APX-005M; EPI-0050; APX-005 | Phase 2 Clinical | Epitomics Inc | Head and Neck Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Skin Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Microsatellite Instability; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Iscalimab | CFZ-533; NVP-CFZ533; OM11-62-MF | Phase 2 Clinical | Novartis Pharma Ag | Rejection of renal transplantation; Myasthenia Gravis; Diabetes Mellitus, Type 1; Rejection of liver transplantation; Sjogren's Syndrome; Arthritis, Rheumatoid; Lupus Nephritis; Graves Disease; Lupus Erythematosus, Systemic; Sjogren-Larsson Syndrome; Hidradenitis Suppurativa | Details |
Anti-CD40 ChiLob7/4 (BioNTech) | Phase 2 Clinical | Biontech Se | Head and Neck Neoplasms; Pancreatic Neoplasms | Details | |
CDX-1140 | CDX-1140 | Phase 2 Clinical | Celldex Therapeutics | Colorectal Neoplasms; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Sarcoma; Breast Neoplasms; Osteosarcoma; Cholangiocarcinoma; Bile Duct Neoplasms; Peritoneal Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Squamous Cell; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Merkel Cell; Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Carcinoma, Renal Cell; Carcinoma; Biliary Tract Neoplasms; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; Uveal melanoma | Details |
Bleselumab | 4D-11; ASKP-1240 | Phase 2 Clinical | Kyowa Hakko Kogyo Co Ltd | Rejection of renal transplantation; Rejection of organ transplantation; Psoriasis; Glomerulosclerosis, Focal Segmental | Details |
Tecaginlimab | BNT-312; GEN-1042 | Phase 2 Clinical | Genmab A/S | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Colorectal Neoplasms; Peripheral Nervous System Neoplasms; Carcinoma, Pancreatic Ductal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Ravagalimab | ABBV-323; PR-1629977 | Phase 2 Clinical | Abbvie Inc | Sjogren's Syndrome; Colitis, Ulcerative | Details |
CD40.RBDv vaccin(LinKinVax) | Phase 2 Clinical | LinKinVax, ANRS, Emerging Infectious Diseases, Vaccine Research Institute (VRI), France | Coronavirus Disease 2019 (COVID-19) | Details | |
DFI-105 | DFI105; DFI-105 | Phase 2 Clinical | Diabetes Free Inc | Diabetes Mellitus, Type 2 | Details |
HPV CD40 HVac | Phase 2 Clinical | LinKinVax | Head and Neck Neoplasms; Oropharyngeal Neoplasms | Details | |
Cifurtilimab | SEA-CD40 | Phase 2 Clinical | Seagen Inc | Head and Neck Neoplasms; Lymphoma, B-Cell; Squamous Cell Carcinoma of Head and Neck; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Lymphoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Melanoma | Details |
MIL-97 | MIL-97 | Phase 2 Clinical | Beijing Mabworks Biotech Co Ltd | Solid tumours; Pancreatic Neoplasms | Details |
Dalnicastobart | LVGN7409; LVGN-7409 | Phase 2 Clinical | Lyvgen Biopharma(HK)Ltd | Ovarian Neoplasms; Head and Neck Neoplasms; Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Papillomavirus Infections; Neoplasms; Uveal melanoma; Sarcoma; Carcinoma, Hepatocellular; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung | Details |
2141-V11 | 2141-V11 | Phase 2 Clinical | The Rockefeller University | Solid tumours; Ganglioglioma; Neoplasms; Skin Neoplasms; Glioblastoma; Urinary Bladder Neoplasms; Glioma | Details |
YH-003 | YH-003; YH003 | Phase 2 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd | Solid tumours; Pancreatic Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma | Details |
Abiprubart | KPL-404 | Phase 2 Clinical | Primatope Therapeutics Inc | Arthritis, Rheumatoid | Details |
NJA-730 | NJA-730; NJA-730a; NJA-730b | Phase 1 Clinical | Napajen Pharma | Autoimmune Diseases | Details |
Selicrelumab | RG-7876; RO-7009789 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms; Pancreatic Neoplasms; Lymphoma, Non-Hodgkin | Details |
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) | Phase 1 Clinical | Baylor College Of Medicine | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
ABBV-428 | ABBV-428; ABBV428 | Phase 1 Clinical | Abbvie Inc | Solid tumours | Details |
MEDI-5083 | MEDI-5083 | Phase 1 Clinical | Astrazeneca Plc, Medimmune | Solid tumours | Details |
NG-350A | NG-350A | Phase 1 Clinical | Akamis Bio Ltd | Neoplasms, Glandular and Epithelial; Neoplasm Metastasis | Details |
SL-172154 | SL-172154 | Phase 1 Clinical | Shattuck Labs Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Myelodysplastic Syndromes; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Leukemia, Myeloid, Acute | Details |
LNF-1901 | LNF-1901; LNF1901 | Phase 1 Clinical | Lunan Pharmaceutical Group Co | Neoplasms | Details |
B-901 | B-901; B901 | Phase 1 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Solid tumours | Details |
SHR-7367 | SHR7367; SHR-7367 | Phase 1 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours; Neoplasms | Details |
SHR-1704 | SHR-1704 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Neoplasms | Details |
IMB-071703 | IMB-071703; IMB071703 | Phase 1 Clinical | Beijng Immunoah Pharma Tech Co Ltd | Solid tumours | Details |
ILB-2101 | ILB-2101 | Phase 1 Clinical | Innolake Biopharm (Hangzhou) Co Ltd | Neoplasms | Details |
HBM-9027 | HBM-9027; HBM9027 | Phase 1 Clinical | Harbour Biomed | Solid tumours; Neoplasms | Details |
BSI-038 | BSI-038 | Phase 1 Clinical | Boaoxin Biotechnology(Nanjing) Co Ltd | Solid tumours | Details |
TQB-2916 | TQB2916; TQB-2916 | Phase 1 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Neoplasms | Details |
RO-7300490 | RO-7300490; RG-6189 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours; Neoplasms | Details |
CD40.HIVRI.Env Vaccine | Phase 1 Clinical | Anrs, LinKinVax | HIV Infections | Details | |
Inezetamab | AMG-994 | Phase 1 Clinical | Amgen Inc | Solid tumours | Details |
BMS-986325 | Y 12XX-hz28-P238K | Phase 1 Clinical | Bristol-Myers Squibb Company | Sjogren's Syndrome | Details |
OPT-101 | Phase 1 Clinical | Op-T LLC | Diabetes Mellitus, Type 1 | Details | |
NWY-001(Biocytogen Pharmaceuticals) | NWY001(Biocytogen Pharmaceuticals); YH008; YH-008; NWY-001(Biocytogen Pharmaceuticals) | Phase 1 Clinical | Eucure Pharmaceutical Technology (Beijing) Co Ltd, Biocytogen Pharmaceuticals (Beijing) Co Ltd | Solid tumours; Hematologic Neoplasms; Neoplasms | Details |
This web search service is supported by Google Inc.